Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA II: Facility Fees Might Be Deferred Until ANDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA appears willing to waive fees for some manufacturers until their first product is approved.


Related Content

US FDA Changes Data Source For GDUFA II Facility Fee Setting
GDUFA II: More Than 2,000 ANDAs Remain Unclaimed, Large Firms Still Dominate
Generic Industry Consolidation Illustrated In ANDA Holder List
GDUFA II: ANDAs, Not Facilities Will Govern Revenue
GDUFA II Will Include Small Business Relief, Priority ANDA Reviews
Generic User Fee Talks Reach 'Final Wording' But Still Not Done
GDUFA Negotiations Shift To 'Tiered' Fee Models
Generic User Fees Need Small Business Waiver, Firms Say; Congress May Agree





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts